AstraZeneca Announces $3.5 Bn Investment in US Expansion

This expansion aligns with AstraZeneca’s broader strategy to achieve $80 billion in total revenue by 2030, as outlined in May.

Pharma giant AstraZeneca has planned to invest $3.5 billion in the United States by the end of 2026, aiming to enhance its research and manufacturing capabilities. The initiative includes $2 billion in new capital, projected to create over 1,000 high-skilled jobs.

The investment will bolster AstraZeneca's footprint in the US, its largest market, accounting for 44% of its total revenue.

Key developments include:

An R&D center in Kendall Square, Cambridge, Massachusetts.

A biologics manufacturing facility in Maryland.

Cell therapy manufacturing on the West and East Coasts.

Specialty manufacturing capabilities in Texas.

This expansion aligns with AstraZeneca’s broader strategy to achieve $80 billion in total revenue by 2030, as outlined in May.

The US market plays a central role in this plan, reflecting the company's focus on accelerating its growth in the region.

AstraZeneca's investments mark a significant step in advancing its research and production capabilities while contributing to local job creation and economic growth.